The University of Cincinnati is spearheading a national clinical trial to identify whether a medicine called Tranexamic Acid (TXA) can improve the conditions of individuals with severe and life-threatening Traumatic Brain Injuries (TB).
Researchers are hopeful that the new drug, which is currently used to stabilize bleeding in victims with conditions ranging from aneurysms and liver transplantation, will improve the lives of those with TBI. The study is designed to test whether TXA, if given to TBI victims immediately after an injury, can improve patients mental recovery.
University of Cincinnati's sprawling hospital and trauma center make them a perfect venue to test whether TBI trauma victims with quick exposure to TXA recover more fully or more quickly than their counterparts who did not receive the drug.
Because Traumatic Brain Injury victims cannot often give consent to participate in the medical trial, the FDA has waived the studies obligation to gain informed consent from all of the participants in the study. Medics will use a battery of indicators to determine whether a TBI victim ought to take part in the study. They will be assessing a victims:
There will be three trauma groups involved in the study. One group of trauma victims will receive the placebo and will receive salt water both at the scene of the evacuation and at the hospital. A second group will receive one dose of the TXA at the scene and a second dose in the hospital. The final and third group will receive two doses of the medicine at the scene and salt water at the hospital.
The study intends to keep all the other treatments of the TBI uniform. There will be no other variations in the patients care.
The experienced Sacramento injury lawyers at Arnold Law Firm have successfully represented Sacramento County residents facing debilitating injuries.
To discuss the circumstances of your case or that of your loved ones, call our firm at (916) 777-7777. We will evaluate your case for free.